

Jong-Lyul Ghim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5333207/publications.pdf>

Version: 2024-02-01

49
papers

375
citations

840119

11
h-index

887659

17
g-index

49
all docs

49
docs citations

49
times ranked

717
citing authors

#	ARTICLE	IF	CITATIONS
1	First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1111-e1120.	1.8	2
2	Associations between HLA-A, -B, and -C alleles and iodinated contrast media-induced hypersensitivity in Koreans. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 107.	0.3	1
3	Pharmacokinetic equivalence of CT-P17 to high concentration (100 µg/ml) reference adalimumab: A randomized phase I study in healthy subjects. <i>Clinical and Translational Science</i> , 2021, 14, 1280-1291.	1.5	11
4	Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers. <i>Xenobiotica</i> , 2020, 50, 288-296.	0.5	3
5	Antiepileptic drug-induced severe cutaneous adverse reactions and HLA alleles: A report of five cases with lymphocyte activation test. <i>Translational and Clinical Pharmacology</i> , 2019, 27, 64.	0.3	5
6	Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 880-889.	1.0	7
7	A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males. <i>BioDrugs</i> , 2019, 33, 173-181.	2.2	14
8	Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects. <i>BioMed Research International</i> , 2019, 2019, 1-6.	0.9	5
9	Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 905-912.	1.0	5
10	Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1157-1164.	2.0	5
11	Development of a Physiologically Based Pharmacokinetic Model of Ethionamide in the Pediatric Population by Integrating Flavin-Containing Monooxygenase 3 Maturational Changes Over Time. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1347-1360.	1.0	6
12	THE EFFECTS OF CANDIDATE GENE IN PKPD PATHWAY ON ANTIPSYCHOTICS-INDUCED AMENORRHEA IN FEMALE SCHIZOPHRENIA PATIENTS. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-10-24.	0.0	0
13	Development of Next Generation Sequencing panel including cancer risk gene and drug-metabolizing enzymes. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-10-18.	0.0	0
14	Effects of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-14-15.	0.0	0
15	Inhibition of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 by Sophorea Radix extracts in human liver microsomes. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-14-17.	0.0	0
16	Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report. <i>Journal of Korean Medical Science</i> , 2017, 32, 1542.	1.1	1
17	Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3543-3550.	2.0	7
18	Pharmacokinetics of atorvastatin and sustained-release metformin fixed-dose combination tablets: two randomized, open-label, 2-way crossover studies in healthy male subjects under fed conditions. <i>Translational and Clinical Pharmacology</i> , 2017, 25, 190.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Effects of mirodenafil on the hemodynamics in hypertensive patients taking amlodipine. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 90.	0.3	0
20	Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3493-3499.	2.0	4
21	Population plasma and urine pharmacokinetics of ivabradine and its active metabolite S18982 in healthy Korean volunteers. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 439-449.	1.0	5
22	Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 576-580.	1.0	16
23	The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to <i>CYP2C19</i> and <i>CYP3A5</i> genotypes. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 301-312.	1.1	21
24	Population Pharmacokinetic-Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects. <i>Clinical Therapeutics</i> , 2016, 38, 2610-2621.	1.1	8
25	Population pharmacokinetics of levofloxacin in Korean patients. <i>Journal of Chemotherapy</i> , 2016, 28, 308-313.	0.7	12
26	Development of a validated liquid chromatography-tandem mass spectrometry assay for the quantification of simvastatin acid, the active metabolite of simvastatin, in human plasma. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 22.	0.3	0
27	Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 595-608.	0.7	31
28	Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3571.	2.0	7
29	Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 147-153.	0.3	6
30	Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 66-74.	0.3	0
31	Genetic polymorphisms of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in Vietnamese-Koreans. <i>Translational and Clinical Pharmacology</i> , 2014, 22, 70.	0.3	8
32	Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation. <i>Journal of Lipid Research</i> , 2014, 55, 2334-2342.	2.0	21
33	The effect of <i>Ginkgo biloba</i> extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 821-830.	1.1	17
34	The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 850-857.	1.0	9
35	Population Pharmacokinetic Analysis of Simvastatin and its Active Metabolite with the Characterization of Atypical Complex Absorption Kinetics. <i>Pharmaceutical Research</i> , 2014, 31, 1801-1812.	1.7	13
36	The effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 1005-1011.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Evaluation of Pharmacokinetic and Pharmacodynamic Profiles and Tolerability After Single (2.5, 5, or 10 mg) Doses of Tadalafil in Healthy Korean Volunteers. <i>Clinical Therapeutics</i> , 2013, 35, 819-835.	1.1	14
38	Effect of HNF4A genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 175-179.	0.7	6
39	Comparison of Pharmacokinetic Characteristics and Safety Between JW Amlodipine Tablet 5 mg and NovarscA Tablet 5 mg in Healthy Male Volunteers. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2013, 21, 95.	0.1	1
40	A Simple Dosing Scheme for Intravenous Busulfan Based on Retrospective Population Pharmacokinetic Analysis in Korean Patients. <i>Korean Journal of Physiology and Pharmacology</i> , 2012, 16, 273.	0.6	12
41	Comparison of Pharmacokinetics and Safety of Two Formulations of Letrozole (2.5 mg) in Healthy Male Volunteers. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2012, 20, 135.	0.1	0
42	Comparison of Pharmacokinetic Characteristics and the Safety between Amlodipine Maleate Tablet 5 mg and Amlodipine Besylate Tablet 5 mg. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2012, 20, 42.	0.1	0
43	Pharmacokinetic Comparison of 2 Formulations of Anastrozole (1 mg) in Healthy Korean Male Volunteers: A Randomized, Single-Dose, 2-Period, 2-Sequence, Crossover Study. <i>Clinical Therapeutics</i> , 2012, 34, 305-313.	1.1	7
44	The pharmacokinetics of letrozole – its association with key body mass metrics. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 557-565.	0.3	8
45	Assessment of the influence of severe renal impairment on the pharmacokinetics of mirodenafil in Korean male volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 880-888.	0.3	2
46	The Development of Automated Bed-allocation Expert System in Clinical Research Ward. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2012, 20, 51.	0.1	0
47	Pharmacokinetic Comparison of Controlled- and Immediate-Release Formulations of Dexibuprofen after Single and Multiple Oral Doses in Fasting Healthy Male Korean Volunteers. <i>Clinical Therapeutics</i> , 2011, 33, 1132-1141.	1.1	0
48	Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. <i>Clinical Therapeutics</i> , 2010, 32, 1178-1187.	1.1	62
49	Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: An open-label, randomized-sequence, three-treatment, three-way crossover study. <i>Clinical Therapeutics</i> , 2009, 31, 1046-1053.	1.1	8